Simple HealthKit is taking on health equity with at-home diagnostics, treatment

In its quest to offer healthcare that’s high-quality, accessible and affordable, Simple HealthKit is expanding its portfolio of diagnostic testing to include diabetes, sexual health and the “tripledemic,” which is COVID, the flu and RSV.
Simple HealthKit is operating in a global diabetes diagnostic market expected to reach $42.4 billion by 2026 and the global STD market forecasted to be valued at $141 billion by 2030. The diagnostic market has also made a big shift to at-home, driven by companies like Everlywell, and supplemented by startups all over the world, including Senzo, Healthtracka, T

リンク元